Trospium chloride controlled release

Drug Profile

Trospium chloride controlled release

Alternative Names: Regurin XL; Sanctura XR; Trospium chloride extended release

Latest Information Update: 22 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Indevus Pharmaceuticals
  • Developer Endo Pharmaceuticals Solutions
  • Class Antispasmodics; Benzhydryl compounds; Benzilates; Esters; Nortropanes; Small molecules; Spiro compounds
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Overactive bladder

Most Recent Events

  • 19 Jan 2018 Speciality European Pharma rebrands itself as Contura
  • 12 Oct 2012 First generic equivalent approved in USA for Overactive bladder
  • 26 Sep 2009 Quintiles Transnational and Allergan agree to co-promote Extended-release trospium chloride in the USA for Overactive bladder
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top